Evidence check: Stuhlprobe in the context of blood sugar

Stool testing in the context of blood sugar is an emerging area based on the gut microbiome's role in metabolism. Research indicates that gut bacteria influence insulin sensitivity and glucose regulation via short-chain fatty acids, bile acids, and inflammation. However, the evidence is largely mechanistic and associative, not yet sufficient for clinical guidelines. Direct-to-consumer stool tests may offer correlations but lack diagnostic accuracy for blood sugar control. They can complement traditional measures (fasting glucose, HbA1c, OGTT) but should not replace them. The field is promising but limited by small studies, confounding factors, and lack of standardization. Marketing often overstates the predictive power. Therefore, the evidence level is 'mixed': plausible biological pathways exist, but robust clinical validation is missing. Consumers should interpret results cautiously and prioritize established biomarkers for diabetes risk assessment.